{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:08:38Z","timestamp":1748318918337,"version":"3.41.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRCPJT\\100017","PPRCPJT\\100017","PPRCPJT\\100017"],"award-info":[{"award-number":["PPRCPJT\\100017","PPRCPJT\\100017","PPRCPJT\\100017"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["208041-2019","208041-2019"],"award-info":[{"award-number":["208041-2019","208041-2019"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Glioma patients often suffer from psychiatric and neurological conditions. However, little is known about the patterns of use of psychotropic drugs pre- and post-glioma diagnosis. Therefore, we assessed temporal patterns of psychotropic prescriptions among glioma patients, compared to an age and sex matched comparison cohort in four European countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Incident gliomas were identified in Wales from the Secured Anonymized Information Linkage Databank (2005\u20132016) and population-based registries in Denmark (2001\u20132016), Norway (2006\u20132019), and Sweden (2008\u20132018). From each data source, a cancer-free comparison cohort was matched to the glioma cases by age and sex. We calculated rates of new psychotropic prescriptions and any psychotropic prescriptions during the 2 years prior to and post glioma diagnosis. Analyses were stratified by histological subtypes and subclasses of psychotropic medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 16,007 glioma patients. The rate of new psychotropic drug use increased from 7 months before diagnosis, peaking around the month of glioma diagnosis (with peak rates ranging from 227 to 753 new psychotropic drugs per 1000 person-months). New use remained substantially higher among glioma patients than comparators throughout the 2-year follow-up period after glioma diagnosis, though rates of new use continued to decline throughout. New use was largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives. Patterns were similar when analyses were stratified by histological subtype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Psychotropic drug use among glioma patients was high, and elevations observed around the time of cancer diagnosis, largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives, are likely associated with the consequences of the disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-04996-0","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:07:38Z","timestamp":1744290458000},"page":"383-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales"],"prefix":"10.1007","volume":"173","author":[{"given":"Sarah M.","family":"Baxter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Bjerkvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cardwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"Habel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannicke","family":"Igland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Klungs\u00f8yr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Miletic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Jalil","family":"Sharifian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bl\u00e1naid","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"4996_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.26494","volume":"118","author":"AS Darefsky","year":"2012","unstructured":"Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118:2163\u20132172. https:\/\/doi.org\/10.1002\/cncr.26494","journal-title":"Cancer"},{"key":"4996_CR2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ejca.2014.05.019","volume":"50","author":"VKY Ho","year":"2014","unstructured":"Ho VKY, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, Visser O (2014) Changing incidence and improved survival of gliomas. Eur J Cancer 50:2309\u20132318. https:\/\/doi.org\/10.1016\/j.ejca.2014.05.019","journal-title":"Eur J Cancer"},{"key":"4996_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/neuonc\/noac216","volume":"25","author":"JAF Koekkoek","year":"2022","unstructured":"Koekkoek JAF, van der Meer PB, Pace A, Hertler C, Harrison R, Leeper HE, Forst DA, Jalali R, Oliver K, Philip J, Taphoorn MJB, Dirven L, Walbert T (2022) Palliative care and end-of-life care in adults with malignant brain tumors. Neuro Oncol 25:447\u2013456. https:\/\/doi.org\/10.1093\/neuonc\/noac216","journal-title":"Neuro Oncol"},{"key":"4996_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/CCO.0000000000000876","volume":"34","author":"PB van der Meer","year":"2022","unstructured":"van der Meer PB, Taphoorn MJB, Koekkoek JAF (2022) Management of epilepsy in brain tumor patients. Curr Opin Oncol 34:685\u2013690","journal-title":"Curr Opin Oncol"},{"key":"4996_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ane.12285","volume":"131","author":"JP Posti","year":"2015","unstructured":"Posti JP, Bori M, Kauko T, Sankinen M, Nordberg J, Rahi M, Frantz\u00e9n J, Vuorinen V, Sipil\u00e4 JO (2015) Presenting symptoms of glioma in adults. Acta Neurol Scand 131:88\u201393. https:\/\/doi.org\/10.1111\/ane.12285","journal-title":"Acta Neurol Scand"},{"key":"4996_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11060-017-2607-5","volume":"135","author":"BK Rasmussen","year":"2017","unstructured":"Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, N\u00f8rg\u00e5rd BM, Guldberg R, Gradel KO (2017) Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol 135:571\u2013579. https:\/\/doi.org\/10.1007\/s11060-017-2607-5","journal-title":"J Neurooncol"},{"key":"4996_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/djq458","volume":"103","author":"AG Rooney","year":"2011","unstructured":"Rooney AG, Carson A, Grant R (2011) Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst 103:61\u201376. https:\/\/doi.org\/10.1093\/jnci\/djq458","journal-title":"J Natl Cancer Inst"},{"key":"4996_CR8","doi-asserted-by":"publisher","first-page":"94932","DOI":"10.18632\/oncotarget.19843","volume":"8","author":"J Huang","year":"2017","unstructured":"Huang J, Zeng C, Xiao J, Zhao D, Tang H, Wu H, Chen J (2017) Association between depression and brain tumor: a systematic review and meta-analysis. Oncotarget 8:94932\u201394943. https:\/\/doi.org\/10.18632\/oncotarget.19843","journal-title":"Oncotarget"},{"key":"4996_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/ndt.S65874","volume":"11","author":"FW Boele","year":"2015","unstructured":"Boele FW, Rooney AG, Grant R, Klein M (2015) Psychiatric symptoms in glioma patients: from diagnosis to management. Neuropsychiatr Dis Treat 11:1413\u20131420. https:\/\/doi.org\/10.2147\/ndt.S65874","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4996_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11060-023-04326-2","volume":"163","author":"LKP Regli","year":"2023","unstructured":"Regli LKP, Huijs SMH, Pasmans RCOS, Leue C, Dijkstra JB, Eekers DBP, Hovinga KE, Anten MHME, Hoeben A, Broen MPG (2023) Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study. J Neurooncol 163:185\u2013194. https:\/\/doi.org\/10.1007\/s11060-023-04326-2","journal-title":"J Neurooncol"},{"key":"4996_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jns.2019.07.026","volume":"404","author":"N Samudra","year":"2019","unstructured":"Samudra N, Zacharias T, Plitt A, Lega B, Pan E (2019) Seizures in glioma patients: an overview of incidence, etiology, and therapies. J Neurol Sci 404:80\u201385. https:\/\/doi.org\/10.1016\/j.jns.2019.07.026","journal-title":"J Neurol Sci"},{"key":"4996_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12885-021-07939-w","volume":"21","author":"I Ryd\u00e9n","year":"2021","unstructured":"Ryd\u00e9n I, Thurin E, Carstam L, Smits A, Gulati S, Henriksson R, Salvesen \u00d8, Store Jakola A (2021) Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study. BMC Cancer 21:248. https:\/\/doi.org\/10.1186\/s12885-021-07939-w","journal-title":"BMC Cancer"},{"key":"4996_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/nop\/npaa022","volume":"7","author":"D Gramatzki","year":"2020","unstructured":"Gramatzki D, Rogers JL, Neidert MC, Hertler C, Le Rhun E, Roth P, Weller M (2020) Antidepressant drug use in glioblastoma patients: an epidemiological view. Neurooncol Pract 7:514\u2013521. https:\/\/doi.org\/10.1093\/nop\/npaa022","journal-title":"Neurooncol Pract"},{"key":"4996_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11060-018-03007-9","volume":"140","author":"KM Knudsen-Baas","year":"2018","unstructured":"Knudsen-Baas KM, Johannesen TB, Myklebust T\u00c5, Aarseth JH, Owe JF, Gilhus NE, Storstein AM (2018) Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. J Neurooncol 140:739\u2013748. https:\/\/doi.org\/10.1007\/s11060-018-03007-9","journal-title":"J Neurooncol"},{"key":"4996_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41419-024-06779-3","volume":"15","author":"JR Jacob","year":"2024","unstructured":"Jacob JR, Palanichamy K, Chakravarti A (2024) Antipsychotics possess anti-glioblastoma activity by disrupting lysosomal function and inhibiting oncogenic signaling by stabilizing PTEN. Cell Death Dis 15:414. https:\/\/doi.org\/10.1038\/s41419-024-06779-3","journal-title":"Cell Death Dis"},{"key":"4996_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020582","author":"M Stella","year":"2023","unstructured":"Stella M, Baiardi G, Pasquariello S, Sacco F, Dellacasagrande I, Corsaro A, Mattioli F, Barbieri F (2023) Antitumor potential of antiepileptic drugs in human glioblastoma: pharmacological targets and clinical benefits. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020582","journal-title":"Biomedicines"},{"key":"4996_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/fcp.12712","volume":"36","author":"B Abadi","year":"2022","unstructured":"Abadi B, Shahsavani Y, Faramarzpour M, Rezaei N, Rahimi HR (2022) Antidepressants with anti-tumor potential in treating glioblastoma: a narrative review. Fundam Clin Pharmacol 36:35\u201348. https:\/\/doi.org\/10.1111\/fcp.12712","journal-title":"Fundam Clin Pharmacol"},{"key":"4996_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pds.4145","volume":"26","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Hallas J (2017) New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf 26:223\u2013227. https:\/\/doi.org\/10.1002\/pds.4145","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4996_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/clep.S314959","volume":"13","author":"K Laugesen","year":"2021","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, S\u00f8rensen HT (2021) Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol 13:533\u2013554. https:\/\/doi.org\/10.2147\/clep.S314959","journal-title":"Clin Epidemiol"},{"key":"4996_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1472-6963-9-157","volume":"9","author":"DV Ford","year":"2009","unstructured":"Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, Brown G, Brooks CJ, Thompson S, Bodger O, Couch T, Leake K (2009) The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 9:157. https:\/\/doi.org\/10.1186\/1472-6963-9-157","journal-title":"BMC Health Serv Res"},{"key":"4996_CR21","doi-asserted-by":"publisher","DOI":"10.23889\/sail-databank.1001101","volume-title":"The SAIL databank: 10 years of spearheading data privacy and research utility, 2007\u20132017","author":"K Jones","year":"2017","unstructured":"Jones K, Ford D, Lyons R (2017) The SAIL databank: 10 years of spearheading data privacy and research utility, 2007\u20132017. Swansea University, Swansea. https:\/\/doi.org\/10.23889\/sail-databank.1001101"},{"key":"4996_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6947-9-3","volume":"9","author":"RA Lyons","year":"2009","unstructured":"Lyons RA, Jones KH, John G, Brooks CJ, Verplancke J-P, Ford DV, Brown G, Leake K (2009) The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak 9:3. https:\/\/doi.org\/10.1186\/1472-6947-9-3","journal-title":"BMC Med Inform Decis Mak"},{"key":"4996_CR23","volume-title":"Guidelines for ATC classification and DDD assignment 2024","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2024","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2024) Guidelines for ATC classification and DDD assignment 2024. WHO, Oslo"},{"key":"4996_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1365-2532.1994.1130177.x","volume":"11","author":"N Booth","year":"1994","unstructured":"Booth N (1994) What are the read codes? Health Libr Rev 11:177\u2013182. https:\/\/doi.org\/10.1046\/j.1365-2532.1994.1130177.x","journal-title":"Health Libr Rev"},{"key":"4996_CR25","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Wolters Kluwer\/Lippincott Williams & Wilkins, Philadelphia"},{"key":"4996_CR26","doi-asserted-by":"publisher","first-page":"5448587","DOI":"10.1155\/2024\/5448587","volume":"2024","author":"I Bojani\u0107","year":"2024","unstructured":"Bojani\u0107 I (2024) Use of antidepressant and anxiolytic drugs in Scandinavian Countries between 2006 and 2021: a prescription database study. Depress Anxiety 2024:5448587. https:\/\/doi.org\/10.1155\/2024\/5448587","journal-title":"Depress Anxiety"},{"key":"4996_CR27","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.3399\/bjgp.2021.0561","volume":"72","author":"C Archer","year":"2022","unstructured":"Archer C, MacNeill SJ, Mars B, Turner K, Kessler D, Wiles N (2022) Rise in prescribing for anxiety in UK primary care between 2003 and 2018: a population-based cohort study using clinical practice research datalink. Br J Gen Pract 72:e511\u2013e518. https:\/\/doi.org\/10.3399\/bjgp.2021.0561","journal-title":"Br J Gen Pract"},{"key":"4996_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11912-023-01410-8","volume":"25","author":"NS Hauff","year":"2023","unstructured":"Hauff NS, Storstein A (2023) Seizure management and prophylaxis considerations in patients with brain tumors. Curr Oncol Rep 25:787\u2013792. https:\/\/doi.org\/10.1007\/s11912-023-01410-8","journal-title":"Curr Oncol Rep"},{"key":"4996_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/neuonc\/now119","volume":"19","author":"TS Armstrong","year":"2017","unstructured":"Armstrong TS, Shade MY, Breton G, Gilbert MR, Mahajan A, Scheurer ME, Vera E, Berger AM (2017) Sleep-wake disturbance in patients with brain tumors. Neuro Oncol 19:323\u2013335. https:\/\/doi.org\/10.1093\/neuonc\/now119","journal-title":"Neuro Oncol"},{"key":"4996_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/nop\/npad019","volume":"10","author":"PB van der Meer","year":"2023","unstructured":"van der Meer PB, Dirven L, Hertler C, Boele FW, Batalla A, Walbert T, Rooney AG, Koekkoek JAF (2023) Depression and anxiety in glioma patients. Neurooncol Pract 10:335\u2013343. https:\/\/doi.org\/10.1093\/nop\/npad019","journal-title":"Neurooncol Pract"},{"key":"4996_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11060-023-04270-1","volume":"162","author":"JA Martin","year":"2023","unstructured":"Martin JA, Hart NH, Bradford N, Naumann F, Pinkham MB, Pinkham EP, Holland JJ (2023) Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review. J Neurooncol 162:25\u201344. https:\/\/doi.org\/10.1007\/s11060-023-04270-1","journal-title":"J Neurooncol"},{"key":"4996_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clineuro.2018.06.016","volume":"172","author":"C Shi","year":"2018","unstructured":"Shi C, Lamba N, Zheng LJ, Cote D, Regestein QR, Liu CM, Tran Q, Routh S, Smith TR, Mekary RA, Broekman MLD (2018) Depression and survival of glioma patients: a systematic review and meta-analysis. Clin Neurol Neurosurg 172:8\u201319. https:\/\/doi.org\/10.1016\/j.clineuro.2018.06.016","journal-title":"Clin Neurol Neurosurg"},{"key":"4996_CR33","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.3390\/jcm11164811","volume":"11","author":"Y Hu","year":"2022","unstructured":"Hu Y, Deng F, Zhang L, Hu K, Liu S, Zhong S, Yang J, Zeng X, Peng X (2022) Depression and quality of life in patients with gliomas: a narrative review. J Clin Med 11:4811","journal-title":"J Clin Med"},{"key":"4996_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/neuonc\/noac185","volume":"25","author":"FW Boele","year":"2022","unstructured":"Boele FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, van Thuijl HF, Lorenz LMC, Wesseling P, Lagerwaard FJ, Taphoorn MJB, Kouwenhoven MCM, Snijders TJ, Douw L, Klein M (2022) Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades. Neuro Oncol 25:351\u2013364. https:\/\/doi.org\/10.1093\/neuonc\/noac185","journal-title":"Neuro Oncol"},{"key":"4996_CR35","doi-asserted-by":"publisher","first-page":"n1560","DOI":"10.1136\/bmj.n1560","volume":"374","author":"C McKinnon","year":"2021","unstructured":"McKinnon C, Nandhabalan M, Murray SA, Plaha P (2021) Glioblastoma: clinical presentation, diagnosis, and management. BMJ 374:n1560. https:\/\/doi.org\/10.1136\/bmj.n1560","journal-title":"BMJ"},{"key":"4996_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11920-014-0529-x","volume":"17","author":"SM Thekdi","year":"2014","unstructured":"Thekdi SM, Trinidad A, Roth A (2014) Psychopharmacology in cancer. Curr Psychiatry Rep 17:529. https:\/\/doi.org\/10.1007\/s11920-014-0529-x","journal-title":"Curr Psychiatry Rep"},{"key":"4996_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1200\/jco.2011.39.5632","volume":"30","author":"L Traeger","year":"2012","unstructured":"Traeger L, Greer JA, Fernandez-Robles C, Temel JS, Pirl WF (2012) Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30:1197\u20131205. https:\/\/doi.org\/10.1200\/jco.2011.39.5632","journal-title":"J Clin Oncol"},{"key":"4996_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","volume":"84","author":"B Hicks","year":"2023","unstructured":"Hicks B, Kaye JA, Azoulay L, Kristensen KB, Habel LA, Potteg\u00e5rd A (2023) The application of lag times in cancer pharmacoepidemiology: a narrative review. Ann Epidemiol 84:25\u201332. https:\/\/doi.org\/10.1016\/j.annepidem.2023.05.004","journal-title":"Ann Epidemiol"},{"key":"4996_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.5547","volume":"32","author":"EK Acton","year":"2023","unstructured":"Acton EK, Willis AW, Hennessy S (2023) Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf 32:9\u201318. https:\/\/doi.org\/10.1002\/pds.5547","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4996_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/nop\/npw032","volume":"4","author":"A Wasilewski","year":"2017","unstructured":"Wasilewski A, Serventi J, Kamalyan L, Wychowski T, Mohile N (2017) Acute care in glioblastoma: the burden and the consequences. Neuro-Oncology Practice 4:248\u2013254. https:\/\/doi.org\/10.1093\/nop\/npw032","journal-title":"Neuro-Oncology Practice"},{"key":"4996_CR41","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s44220-024-00275-5","volume":"2","author":"MNG van Genderen","year":"2024","unstructured":"van Genderen MNG, Belgers V, Niers JM, Douw L, R\u00f6ttgering JG, Gorter M, Blom MEC, Barkhof F, Klein M, Eijgelaar RS, De Witt Hamer PC (2024) Tumor location is associated with mood dysfunction in patients with diffuse glioma. Nature Mental Health 2:853\u2013864. https:\/\/doi.org\/10.1038\/s44220-024-00275-5","journal-title":"Nature Mental Health"},{"key":"4996_CR42","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","volume":"72","author":"A Baftiu","year":"2016","unstructured":"Baftiu A, Johannessen Landmark C, Rusten IR, Feet SA, Johannessen SI, Larsson PG (2016) Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders\u2014a pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 72:1245\u20131254. https:\/\/doi.org\/10.1007\/s00228-016-2092-3","journal-title":"Eur J Clin Pharmacol"},{"key":"4996_CR43","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1007\/s00432-023-04600-w","volume":"149","author":"U Goerling","year":"2023","unstructured":"Goerling U, Hinz A, Koch-Gromus U, Hufeld JM, Esser P, Mehnert-Theuerkauf A (2023) Prevalence and severity of anxiety in cancer patients: results from a multi-center cohort study in Germany. J Cancer Res Clin Oncol 149:6371\u20136379. https:\/\/doi.org\/10.1007\/s00432-023-04600-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"4996_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"4996_CR45","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","volume":"164","author":"SH Torp","year":"2022","unstructured":"Torp SH, Solheim O, Skjulsvik AJ (2022) The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know\u2014a minireview. Acta Neurochir 164:2453\u20132464. https:\/\/doi.org\/10.1007\/s00701-022-05301-y","journal-title":"Acta Neurochir"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04996-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:44:51Z","timestamp":1748249091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04996-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04996-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP reports participation in research projects funded by Alcon, Almirall, Astellas, Astrazeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. ML, JE and JR report participation in research projects funded by Janssen, Swedish Orphan BioVitrum (SOBI), Bayer, Novartis, AbbVie, Novo Nordisk, Pfizer, all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. JI reports participation in regulator-mandated post-authorisation safety studies (PASS) funded by Sanofi, Pfizer and Novartis, all with funds paid to the institution where she was employed (no personal fees). AL reports participation in PASS funded by Amgen, Sanofi, Pfizer and Novartis, all with funds paid to the institution where she was employed (no personal fees)].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Approval was obtained for each of the individual datasets from: the Information Governance Review Panel (Wales), the Danish Data Protection Agency, the Regional Committee for Medical and Health Research Ethics (2018\/2125\/REK vest) (Norway), and the Swedish Ethical Authority, Statistics Sweden and the Swedish National Board of Health and Welfare].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}